Companies › Sound Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ebselen (SPI-1005) Glutathione peroxidase mimetic | GPX1, GPX2, GPX3, GPX4 | Phase 3 | Meniere's Disease; Hearing Loss | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06859788 | Ebselen (SPI-1005) | Phase 3 | Meniere's Disease | Other | Dec 2026 |
| NCT06340633 | Ebselen (SPI-1005) | Phase 2 | Hearing Loss | Other | Dec 2026 |
Cash of 655m CNY on 2025-12-31; operating cash flow positive
Intuitive Surgical Palvella Therapeutics Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.